Dog Lung Cancer May Have a Path to More Personalized Treatment
Dog lung cancer is a serious diagnosis, and a new study brings a meaningful discovery: some canine lung tumors carry specific gene mutations that are also found in human cancers. In 15% of the tumors studied, researchers found changes in genes called HER2 and BRAF. These same mutations are already targets for drugs used in human cancer treatment. That opens the door — still far down the road — to more tailored cancer therapy for dogs in the future.
The findings were published in Veterinary Sciences and are still at an early research stage. No new treatment is available yet. But for dog owners facing a lung cancer diagnosis, this is part of a growing effort to understand canine cancer at the genetic level, so that future vets may be able to match each tumor to the treatment most likely to work.
Why Lung Cancer in Dogs Is So Difficult to Treat
Lung cancer occurs less often in dogs than in people, but when it does appear, it can be aggressive. Surgery is often the first option when the tumor is found early. Once the cancer has spread, however, choices become limited and outcomes are often poor.
Part of the challenge is that not all lung tumors behave the same way. Even within a single cancer type, individual tumors can grow at different speeds, spread in different directions, and respond differently to the same drugs. Researchers believe that looking at a tumor’s genetics can help explain these differences — and eventually point to better treatment choices. This approach is called precision oncology, and it is already changing human cancer care. Scientists are now asking whether the same idea could help dogs.
How the Study Was Done
To explore this question, researchers examined 20 surgically removed canine lung tumors. All were the type called pulmonary adenocarcinoma — the most common kind of lung cancer in dogs. (Adenocarcinoma means the cancer started in the cells that line the inside of the lung.)
The team also studied three canine lung-cancer cell lines — living cancer cells grown in a controlled lab setting, used alongside the real tumor samples.
The key analysis was a hotspot mutation screen: a method that checks the most commonly mutated spots in known cancer-related genes. Think of it like scanning the most error-prone sections of a long document for typos. The researchers focused on three genes well known in both human and dog cancers:
- HER2 — a gene that, when mutated, signals cells to grow faster than normal
- BRAF — a gene involved in telling cells to divide; mutations here appear in many different cancers
- KRAS — another growth-signaling gene linked to uncontrolled cell division
What the Study Found
Mutations Appeared in a Notable Share of Tumors
Out of 20 canine lung tumors examined:
- The HER2 V659E mutation was found in 3 of 20 tumors (15%)
- The BRAF V595E mutation was also found in 3 of 20 tumors (15%)
- The KRAS G12V mutation appeared in 1 of 20 tumors (5%)
In plain terms: roughly 1 in 7 dog lung tumors carried one of these identifiable mutations. These are the same kinds of mutations that researchers have spent decades studying in human patients, which means a large body of existing knowledge could potentially apply to dogs as well.
Why These Mutations Could Matter for Future Treatment
Scientists pay close attention to mutations like HER2, BRAF, and KRAS because drugs designed to block their effects already exist for human patients. HER2-targeting drugs are used in human breast and gastric cancers. BRAF inhibitors are used in certain melanomas and other tumor types.
Finding that a subset of dog lung tumors carry these same mutations raises a logical research question: could similar targeted drugs help dogs? The honest answer right now is we don’t know. This study does not show that human drugs are safe or effective in dogs, and they should not be given based on this finding alone. But it points researchers toward a specific set of questions worth testing in future studies.
What This Means for Dog Owners
This Is Early-Stage Research
It is important to be clear about what this study does and does not mean for your dog today. This was a small laboratory analysis — not a clinical trial. No new drug has been tested in dogs based on these results, and no treatment change is recommended at this time.
What this study does is help build the scientific foundation needed before better treatments can be developed. Before targeted therapies can ever be tested in dogs, researchers need to know which tumors carry which mutations. This study contributes that groundwork.
If Your Dog Has Been Diagnosed With Lung Cancer
Here are practical steps you can take right now:
- Ask about mutation testing. Some veterinary cancer centers can already test tumor tissue for genetic mutations. This is not yet standard practice everywhere, but it may become more widely available as the science grows.
- See a veterinary oncologist. A board-certified specialist in veterinary cancer stays current with the latest research, knows about any available clinical trials, and can discuss the full range of treatment options for your dog’s specific situation.
- Don’t wait on symptoms. Lung cancer in dogs is often caught late because early signs can be subtle. A persistent cough, labored breathing, unexplained weight loss, or unusual tiredness all warrant a vet visit sooner rather than later.
When to Call Your Veterinarian
Seek a veterinary evaluation if your dog shows:
- A cough that doesn’t go away or gradually gets worse
- Difficulty breathing or rapid breathing while resting
- Reduced appetite or unexplained weight loss
- Unusual fatigue or reluctance to exercise
- Occasional coughing up blood or discolored mucus
Lung conditions have many possible causes, and getting a diagnosis early always improves your options.
Study Limitations to Keep in Mind
This study had a small sample size — just 20 tumors. With such a limited number, it is hard to know how well the results represent all canine lung cancers. The mutations found here might appear at different rates in a larger group of dogs.
The study also focused only on specific hotspot mutations in three genes. Many other genes involved in cancer were not examined, so the full genetic picture of canine lung tumors remains incomplete.
Most importantly, the study showed that certain mutations exist in dog lung tumors — but it did not test whether any targeted drugs actually worked against those tumors. That step requires future experiments and, eventually, clinical trials. The researchers themselves caution that the safety of human targeted drugs in dogs has not been established, and these drugs should not guide treatment without proper evidence from veterinary oncology.
The Bottom Line
A study of 20 canine lung tumors found that 15% carried mutations in the HER2 or BRAF genes — the same mutations that are important treatment targets in human cancer medicine. A smaller number (5%) carried a KRAS mutation. These findings suggest that a portion of dog lung cancers share a genetic feature with some human tumors, which could one day open the door to more personalized treatment approaches for dogs.
No new treatment is available based on these results today, and researchers are clear that much more work is needed before targeted therapies could be used in dogs. But this is exactly the kind of foundational science that moves veterinary oncology forward. If your dog has been diagnosed with lung cancer, a conversation with a veterinary oncologist is the best first step toward understanding every available option.
This article summarizes peer-reviewed research for educational purposes. Always consult with your veterinarian for personalized advice about your pet’s health and behavior.